CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analogue incorporating a drug affinity complex (DAC) that significantly extends its plasma half-life compared to standard CJC-1295. The DAC modification enables covalent binding to serum albumin, producing sustained GHRH-receptor activity in preclinical models. Extensively studied for its effects on pulsatile GH secretion patterns and IGF-1 axis regulation. Available in 2mg and 5mg lyophilised vials.




Reviews
There are no reviews yet.